Glenmark gets tentative nod from US FDA for migraine tablets

PTI New Delhi | Updated on March 12, 2018 Published on September 20, 2012

Glenmark Pharmaceuticals has received tentative approval from the US health regulator for its generic Rizatriptan Benzoate tablets used for treating migraine attacks.

The company’s US arm Glenmark Generics Inc USA has received tentative approval for Rizatriptan Benzoate tablets from the US Food and Drug Administration (US FDA), Glenmark Pharmaceuticals said in a statement today.

The tablets are generic version of drug major Merck’s Maxalt tablets, it added.

Quoting IMS Health data, the company said Rizatriptan Benzoate immediate release tablets achieved sales worth $315 million for the 12-month period ended June 30, 2012.

The company’s portfolio consists of 81 products authorised for distribution in the US market and 41 abbreviated new drug applications (ANDAs) pending approval with the US FDA.

Shares of Glenmark Pharmaceuticals were trading at Rs 416 per scrip on the BSE in the afternoon trade, up 0.96 per cent from their previous close.

Published on September 20, 2012
This article is closed for comments.
Please Email the Editor